UMH PROPERTIES, INC. WILL HOST FIRST QUARTER 2021 FINANCIAL RESULTS WEBCAST AND CONFERENCE CALL

FREEHOLD, NJ, April 05, 2021 (GLOBE NEWSWIRE) — UMH Properties, Inc. (NYSE:UMH), a real estate investment trust (REIT) specializing in manufactured home communities, announced that it will host its First Quarter 2021 Financial Results Webcast and Conference Call. Senior management will discuss the results, current market conditions and future outlook on Friday, May 7, 2021, at 10:00 a.m. Eastern Time.

UMH’s First Quarter 2021 results will be released on Thursday, May 6, 2021, after the close of trading on the New York Stock Exchange, and will be available on the Company’s website at www.umh.reit, in the Financials section.

To participate in the webcast, select the webcast icon on the homepage of the Company’s website at www.umh.reit, in the Upcoming Events section. Interested parties can also participate via conference call by calling toll free 877-513-1898 (domestically) or 412-902-4147 (internationally).

The replay of the conference call will be available at 12:00 p.m. Eastern Time on Friday, May 7, 2021. It will be available until August 1, 2021, and can be accessed by dialing toll free 877-344-7529 (domestically) and 412-317-0088 (internationally) and entering the passcode 10153820. A transcript of the call and the webcast replay will be available at the Company’s website, www.umh.reit.

UMH Properties, Inc., which was organized in 1968, is a public equity REIT that owns and operates 126 manufactured home communities with approximately 23,800 developed homesites. These communities are located in New Jersey, New York, Ohio, Pennsylvania, Tennessee, Indiana, Michigan, Maryland, Alabama and South Carolina. In addition, the Company owns a portfolio of REIT securities.

Contact: Nelli Madden

732-577-4062 

# # # # #



Kessler Topaz Meltzer & Check, LLP – Important Deadline Reminder for Workhorse Group Inc. Investors in Securities Class Action Lawsuit

RADNOR, Pa., April 05, 2021 (GLOBE NEWSWIRE) — The law firm of Kessler Topaz Meltzer & Check, LLP reminds Workhorse Group Inc. (NASDAQ: WKHS) (“Workhorse”) investors that a securities fraud class action lawsuit has been filed in the United States District Court for the Central District of California on behalf of those who purchased or acquired Workhorse securities between July 7, 2020 and February 23, 2021, inclusive (the “Class Period”).


Investor Deadline Reminder: Investors who purchased or acquired Workhorse securities


during the Class Period may,



no later than May 7, 2021



, seek to be appointed as a lead plaintiff representative of the class. For additional information or to learn how to participate in this litigation please contact Kessler Topaz Meltzer & Check, LLP: James Maro, Esq. (484) 270-1453 or Adrienne Bell, Esq. (484) 270-1435; toll free at (844) 887-9500; via e-mail at

[email protected]; orclick https://www.ktmc.com/workhorse-group-class-action-lawsuit?utm_source=PR&utm_medium=link&utm_campaign=workhorse.

Workhorse is a technology company engaged in the development and manufacturing of electric delivery vehicles. In 2016, the United States Postal Service (“USPS”) announced the USPS Next Generation Delivery Vehicle (“NGDV”) project, a competitive multiyear acquisition process for replacing approximately 165,000 package delivery vehicles. Workhorse was one of the companies vying for the NGDV contract, which was thought to be worth approximately $6.3 billion.

The complaint alleges that throughout the Class Period, the defendants continued to indicate that Workhorse would secure the NGDV contract.

However, on February 23, 2021, while the market was open, the USPS issued a press release entitled: U.S. Postal Service Awards Contract to Launch Multi-Billion-Dollar Modernization of Postal Delivery Vehicle Fleet. The press release announced that Oshkosh Defense – not Workhorse – had won the lucrative NGDV contract.

The complaint alleges that, throughout the Class Period, the defendants made false and/or misleading statements and/or failed to disclose that: (1) Workhorse was merely hoping that USPS was going to select an electric vehicle as its NGDV, and had no assurance or indication from USPS that this was the case; (2) Workhorse had concealed the fact that – as revealed by the postmaster general in explaining the ultimate decision not to select an electric vehicle – electrifying the USPS’s entire fleet would be impractical and astronomically expensive; and (3) as a result, the defendants’ public statements were materially false and/or misleading at all relevant times.

Workhorse investors may, no later than May 7, 2021, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP, or other counsel, or may choose to do nothing and remain an absent class member.  A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation.  In order to be appointed as a lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class.  Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff. 

Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country involving securities fraud, breaches of fiduciary duties and other violations of state and federal law. Kessler Topaz Meltzer & Check, LLP is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world.  The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars).  The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com.

CONTACT:

Kessler Topaz Meltzer & Check, LLP
James Maro, Jr., Esq.
Adrienne Bell, Esq.
280 King of Prussia Road
Radnor, PA 19087
(844) 887-9500 (toll free)
[email protected]



Grown Rogue Reports 5th Consecutive Quarter of Positive Adjusted Pro-Forma EBITDA, Record Pro-Forma Revenue of $2M, and Record 73% Cash Margin

Grown Rogue Reports 5th Consecutive Quarter of Positive Adjusted Pro-Forma EBITDA, Record Pro-Forma Revenue of $2M, and Record 73% Cash Margin

MEDFORD, Ore.–(BUSINESS WIRE)–Grown Rogue International Inc. (“Grown Rogue” or the “Company”) (CSE: GRIN) (OTC: GRUSF), a multi-state cannabis company with operations and assets in Oregon and Michigan reports a record quarterly cash margin2 of 73%, helping to drive the 5th consecutive quarter of positive adjusted pro-forma EBITDA1,3 of $0.2M for the three months ended January 31, 2021. The Company also had it largest pro-forma revenue3 in Company history in Q1 2020, despite the first quarter being the most challenging due to industry seasonality.

All amounts are expressed in United States Dollars unless otherwise indicated. Certain metrics, including those expressed on an adjusted basis, are non-IFRS measures.

Financial and Business Highlights

  • Record pro-forma revenue 3 of $2.0M
  • 5th consecutive quarter of positive Adjusted pro-forma EBITDA1,3 of $0.2M
  • Record Cash Margin of 73% in Q1 2021 for Oregon flower production
  • Successfully launched our Certified Fresh Nitrogen Sealed Jars in the Michigan market, obtaining rapid market acceptance and reorders now accounting for approximately 30% of sales in Michigan
  • During and subsequent to quarter-end, raised gross debt and equity (brokered and non-brokered private equity placements) proceeds of CAD$7.6M
  • Started construction to add 40% additional capacity at current Oregon indoor facility and subsequent to quarter end completed construction
  • Subsequent to quarter-end executed an asset purchase agreement to acquire a turn-key 30,000 square foot indoor growing facility in Medford, Oregon and a retail dispensary in Portland, Oregon from HSCP, LLC, a subsidiary of Acreage Holdings Inc.

“Grown Rogue continues to build upon its success with a record quarter for both cash margin and pro-forma revenue, including our 5th consecutive quarter of positive adjusted pro-forma EBITDA to begin 2021,” said Obie Strickler, CEO of Grown Rogue. “Our focused goal remains to efficiently and consistently produce high-quality and low-cost flower, maintain excellent customer relationships and meet the demand of our consumers. With our recent acquisitions and financings, we are well poised for a year of growth and profitability in 2021.”

Management Commentary

Beginning its third year as a publicly traded company, Grown Rogue continued to leverage its simplified business model, resulting in its 5th consecutive quarter of positive Adjusted Pro-Forma EBITDA1,3, improvements and opportunities to scale up production through expansion of existing facilities and acquisitions of new assets. These improvements have led to a record quarter of pro-forma Revenue 3 of $2.0M even during the slowest quarter of our fiscal year. Consistent cash margins2 of near 70%, coupled with the ability to retrofit and implement proven cultivation methods, bodes well for Grown Rogue’s continued strategy and growth.

Highlights by State

Oregon Operations

  • Grown Rogue Indoor flower sold at an average price of $1,361/lb., versus $1,034/lb. in 2020, an increase of over 30% which resulted in a 66% cash margin2
  • Grown Rogue Sungrown flower sold at an average price of $705/lb., versus $681/lb in 2020, an increase of 3% and resulting in a 75% cash margin2
  • More than doubled indoor growing capacity with the acquisition (pending regulatory approval) of a turn-key 30,000 square foot facility. First harvest from this facility is expected in May

Michigan Operations (of our partner Golden Harvests, LLC in which a subsidiary of the Company holds an indirect option to acquire 60% equity interest in Golden Harvests, LLC, pending Municipal and State regulatory approval)

  • Pro-forma3 Revenues of approximately $0.95M, with average selling price exceeding $3k per pound
  • Launched our branded, Certified Fresh Nitrogen Sealed Jars in December quickly gaining market traction. Early results over the last several months showing jars representing approximately one-third of sales and commanding $500-$1000/lb more than bulk sales
  • Construction continued to maximize output from the 80,000 square foot facility. 25,000 square feet are now under cultivation with another 20,000 square feet expected to be online by December 2021
  • Currently operating 2 Adult Use Producer Licenses and 2 Medical Producer Licenses, bringing total plant count capacity to 7,000. The application processes have been started for 4 additional licenses

Selected Financial Information (Complete financial tables have been filed on www.sedar.com)

(Dollars in $000s, share amounts in 000s)

 

 

Three Months Ended January 31,

 

2021

2020

Reported Revenue

$

1,051

1,106

Gross profit, excluding fair value items, as reported

$

578

585

Proforma Revenue3

$

2,001

1,670

Adjusted EBITDA1 (loss)

$

(22)

(5)

Net loss per share

$

(0.01)

(0.00)

Weighted Common Shares Outstanding

 

108,038

72,563

Grown Rogue maintained revenue at $1.1M, comparable to 2020 results.

Pro Forma Adjusted EBITDA1,3 was $0.2M as compared to $0.1M in Q1 2020, driven by increasing sales in Michigan and continued improvements in margin.

Cash Margin for Grown Rogue products2 increased to 73% from 60% in Q1 2020, driven by operational efficiencies and improved pricing.

General and administrative expenses climbed modestly from $670k to $750k, driven in part by increased corporate costs associated with business expansion, as well as higher salaries from recent hires in skilled positions.

The Company generated $123k of cash from operations versus $150k in 2020, with net working capital continuing to improve, after adjusting for the reclassification of convertible debentures from long-term to short-term. The Company anticipates that the remaining debentures will either be converted or retired in the second quarter, using money raised from the private placements.

 

 

Three months ended

 

 

January 31,

Adjusted EBITDA Reconciliation

 

2021

 

2020

Net loss, as reported

$

(995,789)

$

(233,187)

Add back realized fair value amounts included in inventory sold

 

173,598

 

632,630

Add back (deduct) unrealized fair value gain (loss) on growth of biological assets

 

124,311

 

(701,559)

Add back amortization of property & equipment included in cost of sales

 

136,072

 

45,397

 

$

(561,808)

$

(256,719)

Add back accretion expense, as reported

 

248,357

 

68,210

Add back amortization of intangible assets, as reported

 

4,997

 

7,659

Add back amortization of property and equipment, as reported

 

124,381

 

49,677

Add back amortization of right-of-use assets, as reported

 

48,605

 

35,822

Add back share-based compensation expense, as reported

 

88,438

 

 

Add back interest expense, as reported

 

8,527

 

90,514

Deduct unrealized gain on marketable securities, as reported

 

(302,808)

 

Add back unrealized loss on derivative liability

 

319,627

 

Adjusted EBITDA (loss)

$

(21,684)

$

(4,837)

Three months ended

January 31, 2021

Cash Margin analysis

Revenue $

Costs $

Margin %

Grown Rogue products

874,824

237,719

73%

Third party products

Service revenues

176,361

84,153

52%

Asset depreciation included in COGS

136,072

Cost of packaging & other included in COGS

15,142

Total costs of finished cannabis inventory sold, as reported

1,051,185

473,086

55%

Realized fair value amounts in inventory sold, as reported

173,598

Unrealized fair value (gain) on growth of biological assets, as reported

124,311

Totals, as reported

1,051,185

770,995

27%

NOTES:

  1. The Company’s “Adjusted EBITDA” is a non-IFRS measure used by management that does not have any prescribed meaning by IFRS and that may not be comparable to similar measures presented by other companies. The Company defines Adjusted EBITDA as the Company’s net income (loss) for a period, as reported, before interest, taxes, depreciation and amortization, and is further adjusted to remove transaction costs, stock-based compensation expense, accretion expense, gain (loss) on derecognition of derivative liabilities and the effects of fair-value accounting for biological assets and inventory. The Company believes that this is a useful metric to evaluate its operating performance. The following is a reconciliation of the Company’s net income (loss) to Adjusted EBITDA.
  2. The Company has provided Cash Margin Analysis to demonstrate the methodology for calculating its non-IFRS production cost and margin metrics. Cash production costs of Grown Rogue products is calculated by taking the cost of finished cannabis inventory sold and deducting non-cash production costs, packaging and distribution costs, inventory write-offs and adjustments, and cost of products purchased from other Licensed Producers that were sold. Cash cost of sales per gram of dried cannabis sold is calculated by taking cash production costs of Grown Rogue products by total grams of dried cannabis sold in the period. Management believes these measures provide useful information as they remove noncash amortization and packaging costs and provide a benchmark of the Company against its competitors.
  3. The Company has provided unaudited pro-forma revenue information, which assumes that closed and pending mergers and acquisitions in 2020 are included in the Company’s financial results as of the beginning of the quarterly and annual periods in 2020 for the Company and target companies.

NON-IFRS FINANCIAL MEASURES

Cash production costs of Grown Rogue products, EBITDA and Adjusted EBITDA are non-IFRS measures and do not have standardized definitions under IFRS. The Company has also provided unaudited pro-forma financial information, which assumes that closed and pending mergers and acquisitions in 2020 are included in the Company’s financial results as of the beginning of the quarterly and annual periods in 2020. The Company has provided the non-IFRS financial measures, which are not calculated or presented in accordance with IFRS, as supplemental information and in addition to the financial measures that are calculated and presented in accordance with IFRS. These supplemental non-IFRS financial measures are presented because management has evaluated the financial results both including and excluding the adjusted items and believe that the supplemental non-IFRS financial measures presented provide additional perspective and insights when analyzing the core operating performance of the business. These supplemental non-IFRS financial measures should not be considered superior to, as a substitute for or as an alternative to, and should only be considered in conjunction with, the IFRS financial measures presented herein. Accordingly, the following information provides reconciliations of the supplemental non-IFRS financial measures, presented herein to the most directly comparable financial measures calculated and presented in accordance with IFRS.

About Grown Rogue

Grown Rogue International (CSE: GRIN | OTC: GRUSF) is a vertically-integrated, multi-state Cannabis family of brands on a mission to inspire consumers to “enhance experiences” through cannabis. We have combined an expert management team, award winning grow team, state of the art indoor and outdoor manufacturing facilities, and consumer insight based product categorization, to create innovative products thoughtfully curated from “seed to experience.” The Grown Rogue family of products include sungrown and indoor premium flower, along with nitro sealed indoor and sungrown pre-rolls and jars.

FORWARD-LOOKING STATEMENTS

This press release contains statements which constitute “forward‐looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of the Company with respect to future business activities. Forward-looking information is often identified by the words “may,” “would,” “could,” “should,” “will,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “expect” or similar expressions and include information regarding: (i) statements regarding the future direction of the Company (ii) the ability of the Company to successfully achieve its business and financial objectives, (iii) plans for expansion of the Company into Michigan and securing applicable regulatory approvals, and (iv) expectations for other economic, business, and/or competitive factors. Investors are cautioned that forward-looking information is not based on historical facts but instead reflect the Company’s management’s expectations, estimates or projections concerning the business of the Company’s future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the combined company. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: changes in general economic, business and political conditions, including changes in the financial markets; and in particular in the ability of the Company to raise debt and equity capital in the amounts and at the costs that it expects; adverse changes in the public perception of cannabis; decreases in the prevailing prices for cannabis and cannabis products in the markets that the Company operates in; adverse changes in applicable laws; or adverse changes in the application or enforcement of current laws; compliance with extensive government regulation and related costs, and other risks described in the Company’s public disclosure documents filed on www.sedar.com.

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.

SAFE HARBOR STATEMENT

This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) the Company’s financing plans; (ii) trends affecting the Company’s financial condition or results of operations; (iii) the Company’s growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words “may,” “would,” “will,” “expect,” “estimate,” “anticipate,” “believe,” “intend” and similar expressions and variations thereof are intended to identify forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors including the risk disclosed in the Company’s Form 20-F and 6-K filings with the Securities and Exchange Commission.

The Company is indirectly involved in the manufacture, possession, use, sale and distribution of cannabis in the recreational cannabis marketplace in the United States through its indirect operating subsidiaries. Local state laws where its subsidiaries operate permit such activities however, these activities are currently illegal under United States federal law. Additional information regarding this and other risks and uncertainties relating to the Company’s business are disclosed in the Company’s Listing Statement filed on its issuer profile on SEDAR at www.sedar.com. Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or forward-looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.

No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

For further information on Grown Rogue International please visit www.grownrogue.com or contact:

Obie Strickler

Chief Executive Officer

[email protected]

Investor Relations Desk Inquiries

[email protected]

(458) 226-2100

KEYWORDS: United States North America Oregon Michigan

INDUSTRY KEYWORDS: Alternative Medicine Retail Health Agriculture Specialty Natural Resources

MEDIA:

Logo
Logo

First Bank Announces First Quarter 2021 Earnings Conference Call

HAMILTON, N.J., April 05, 2021 (GLOBE NEWSWIRE) — First Bank (Nasdaq Global Market: FRBA) invites participation in a conference call to discuss the Company’s financial and operating performance during its first quarter ended March 31, 2021.

Event: Earnings Conference Call – First Quarter 2021
     
When: Tuesday, April 27, 2021 at 9:00 a.m. Eastern Time
     
Access: Conference Call Dial-In: 844-825-9784
    855-669-9657 (toll-free Canada)
    412-317-5164 (Outside U.S. & Canada)

Patrick L. Ryan, President and CEO, Stephen F. Carman, Executive Vice President and CFO, Peter J. Cahill, Executive Vice President and Chief Lending Officer and Emilio Cooper, Executive Vice President and Chief Deposit Officer will provide an overview of first quarter 2021 results. The management presentation typically lasts approximately fifteen to thirty minutes, followed by investor questions and discussion. The Company’s first quarter results will be released after the market closes on April 26, 2021, and will also be available in the “Investor Relations” section of the Company’s website. Conference replay information is also available on the Company’s website.

About First Bank

First Bank is a New Jersey state-chartered bank with 16 full-service branches in Cinnaminson, Cranbury, Delanco, Denville, Ewing, Flemington, Hamilton, Lawrence, Pennington, Randolph, Somerset and Williamstown, New Jersey, and Doylestown, Trevose, Warminster and West Chester, Pennsylvania. With $2.35 billion in assets as of December 31, 2020, First Bank offers a traditional range of deposit and loan products to individuals and businesses throughout the New York City to Philadelphia corridor. First Bank’s common stock is listed on the Nasdaq Global Market exchange under the symbol “FRBA”.

Contact

Patrick L. Ryan, President and CEO
(609) 643-0168, [email protected] 



CytoDyn Inc. Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against CytoDyn Inc.

PR Newswire

RADNOR, Pa., April 5, 2021 /PRNewswire/ — The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that securities fraud class action lawsuit has been filed against CytoDyn Inc. (OTCMKTS: CYDY) (“CytoDyn”) on behalf of those who purchased or acquired CytoDyn common stock between March 27, 2020 and March 9, 2021, inclusive (the “Class Period”).


Deadline Reminder: Investors who purchased or acquired CytoDyn common stock


during the Class Period may, no later than May 17, 2021, seek to be appointed as a lead plaintiff representative of the class. For additional information or to learn how to participate in this litigation please contact Kessler Topaz Meltzer & Check, LLP: James Maro, Esq. (484) 270-1453 or Adrienne Bell, Esq. (484) 270-1435; toll free at (844) 887-9500; via e-mail at

[email protected]; orclick https://www.ktmc.com/cytodyn-class-action-lawsuit?utm_source=PR&utm_medium=link&utm_campaign=cytodyn

CytoDyn is a biotechnology company that has focused on the development and commercialization of a drug named “Leronlimab” which has long been promoted as a potential therapy for HIV patients. Since the beginning of the global COVID-19 pandemic, CytoDyn began aggressively touting Leronlimab as a treatment for COVID-19. Following CytoDyn’s pivot to hyping Leronlimab as a treatment for COVID-19, CytoDyn’s stock price rose exponentially.

The Class Period commences on March 27, 2020, when CytoDyn issued a press release regarding Leronlimab’s use in treating COVID-19 patients entitled “Leronlimab Used in Seven Patients with Severe COVID-19 Demonstrated Promise with Two Intubated Patients in ICU, Removed from ICU and Extubated with Reduced Pulmonary Inflammation.” Throughout the Class Period, CytoDyn continued to tout Leronlimab as a potential treatment for COVID-19 and to pump up the stock price of CytoDyn while executives aggressively sold shares. Indeed, while CytoDyn’s stock price was sufficiently pumped with the COVID-19 cure hype, long-term shareholders, including defendants Nader Z. Pourhassan, CytoDyn’s Chief Executive Officer, and Michael Mulholland, CytoDyn’s Chief Financial Officer, dumped millions of shares.

Following the cash-out by CytoDyn insiders and long-term shareholders, the defendants’ scheme began to unravel. On Friday, March 5, 2021 after the close of trading, and continuing over that weekend, CytoDyn issued press releases describing the results of the Phase IIb/III data on Leronlimab. The press releases had titles such as “Cytodyn to File Accelerated Rolling Review with MHRA and Interim Order (IO) with Health Canada for COVID-19” and “Cytodyn’s Phase 3 Trial Demonstrates Safety, a 24% Reduction in Mortality and Faster Hospital Discharge for Mechanically Ventilated Critically Ill COVID-19 Patients Treated with Leronlimab.” However, hidden in the press releases was a disclosure that the primary endpoint of the study—lowering all-cause mortality at Day 28— was not statistically significant. Following the issuance of its press releases, CytoDyn was accused of “massaging the data” and squeezing good news out of a failed study, the results of which CytoDyn reportedly sat on pending regulatory discussions.

Following the release of the data, the price of CytoDyn’s common stock fell over 28% to close at $2.91 on March 8, 2021. On March 9, 2021, the price of CytoDyn’s common stock continued to fall, dropping an additional 19% to close at $2.35.

The complaint alleges that, throughout the Class Period, the defendants made false and/or misleading statements and/or failed to disclose that CytoDyn’s development and marketing of Leronlimab as a treatment for COVID-19 was not commercially viable.

CytoDyn investors may, no later than May 17, 2021, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. In order to be appointed as a lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.

Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country involving securities fraud, breaches of fiduciary duties and other violations of state and federal law. Kessler Topaz Meltzer & Check, LLP is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world. The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars). The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com.

CONTACT:
Kessler Topaz Meltzer & Check, LLP
James Maro, Jr., Esq.
Adrienne Bell, Esq.
280 King of Prussia Road
Radnor, PA 19087
(844) 887-9500 (toll free)
[email protected]

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cytodyn-inc-reminder-kessler-topaz-meltzer–check-llp-reminds-investors-of-securities-fraud-class-action-lawsuit-filed-against-cytodyn-inc-301261283.html

SOURCE Kessler Topaz Meltzer & Check, LLP

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts EHang Holdings Limited (EH) Investors to April 19th Deadline in Securities Fraud Lawsuit, Encourages Investors with Losses to Contact the Firm

SAN FRANCISCO, April 05, 2021 (GLOBE NEWSWIRE) — Hagens Berman urges EHang Holdings Limited (NASDAQ: EH) investors with significant losses to submit their losses now. A securities fraud class action has been filed and certain investors may have valuable claims.

Class Period: Dec. 9, 2019 – Feb. 16, 2021
Lead Plaintiff Deadline: Apr. 19, 2021
Visit:www.hbsslaw.com/investor-fraud/ehang
Contact An Attorney Now:[email protected]
844-916-0895

EHang Holdings Limited (EH) Securities Litigation:

The Complaint alleges that throughout the Class Period, Defendants misrepresented and concealed that: (i) E-Hang’s purported regulatory approvals in Europe and North American for its EH216 were for use as a drone, and not for carrying passengers; (ii) its relationship with its purported primary customer, Kunxiang, is a sham; (iii) EHang has only collected on a fraction of its reported sales since its ADS began trading on NASDAQ in December 2019; and (iv) the Company’s manufacturing facilities were practically empty and lacked evidence of advanced manufacturing equipment or employees.

Investors allegedly learned the truth on February 16, 2021, when analyst Wolfpack Research issued a scathing report about the company. Wolfpack Research contends that Kunxiang has entered into sham contracts to benefit EH’s stock price. Wolfpack Research also alleges that EH has exaggerated revenues by reporting sales for which it cannot collect.   Wolfpack Research further avers that EH makes false claims about regulatory approvals the company has purportedly received, misleadingly suggesting the company has commercial approval for its products.

On this news, the price of EHang’s shares dropped $77.79 per share (or 62.7%) in one trading day.

“We’re focused on investor losses and proving EH lied about its revenues, customers and regulatory approvals,” said Reed Kathrein, the Hagens Berman partner leading the investigation.

If you are an EH investor, click here to discuss your legal rights with Hagens Berman.

Whistleblowers: Persons with non-public information regarding EH should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].


About Hagens Berman


Hagens Berman is a national law firm with eight offices in eight cities around the country and over eighty attorneys. The firm represents investors, whistleblowers, workers and consumers in complex litigation.   More about the firm and its successes is located at hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.

Contact:

Reed Kathrein, 844-916-0895



Investor Alert: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against MultiPlan Corporation (MPLN)

PR Newswire

RADNOR, Pa., April 5, 2021 /PRNewswire/ — The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed against MultiPlan Corporation (NYSE: MPLN; MPLN.WS) (“MultiPlan”) f/k/a Churchill Capital Corp. III (“Churchill III”) on behalf of: (1) those who purchased or acquired MultiPlan securities between July 12, 2020 and November 10, 2020, inclusive (the “Class Period”); and (2) all holders of Churchill III Class A common stock entitled to vote on Churchill III’s merger with and acquisition of Polaris Parent Corp. and its consolidated subsidiaries consummated in October 2020 (the “Merger”).


Deadline Reminder:  Investors who purchased or acquired MultiPlan securities


during the Class Period may, no later than April 26, 2021, seek to be appointed as a lead plaintiff representative of the class. For additional information or to learn how to participate in this litigation please contact Kessler Topaz Meltzer & Check, LLP: James Maro, Esq. (484) 270-1453 or Adrienne Bell, Esq. (484) 270-1435; toll free at (844) 887-9500; via e-mail at

[email protected]; orclick https://www.ktmc.com/multiplan-corp-securities-class-action-lawsuit?utm_source=PR&utm_medium=link&utm_campaign=multiplan.

Churchill III was formed in October 2019 as a special purpose acquisition vehicle.  On February 14, 2020, Churchill III completed its initial public offering, selling 110 million ownership units to investors for gross proceeds of $1.1 billion (the “IPO”). Pursuant to the IPO prospectus, Churchill III was required to acquire a target business with an aggregate fair market value of at least 80% of the assets held in trust from the IPO proceeds and to do so within two years of the IPO.

The Class Period commences on July 12, 2020, when Churchill III and MultiPlan, a healthcare cost specialist, issued a joint press release announcing their agreement to combine. The Merger, initially valued at $5.7 billion, would be funded by the IPO proceeds as well as billions of dollars in new debt and equity issuances.

On September 18, 2020, Churchill III issued the proxy statement for the Merger which urged shareholders to vote in favor of the deal (the “Proxy”). The Proxy stated that Churchill had identified MultiPlan as a potential acquisition target soon after the IPO. On the basis of the Proxy, on October 7, 2020, shareholders voted to approve the Merger at a special shareholders meeting. Because of the Proxy, shareholders were prevented from the fully informed opportunity to redeem their shares as was their right. The shares subject to redemption were valued in the Proxy at approximately $10 per share.

On November 11, 2020, one month after the close of the Merger, Muddy Waters published a report on Churchill III titled “MultiPlan: Private Equity Necrophilia Meets The Great 2020 Money Grab”, which was based on extensive non-public sources such as interviews with former MultiPlan executives and other industry experts, as well as proprietary analysis. The report revealed, in part, that: (1) MultiPlan was in the process of losing its largest client, UnitedHealthcare, which was estimated to cost Churchill III up to 35% of its revenues and 80% of its levered free cash flow within two years; (2) MultiPlan was in significant financial decline because of its fundamentally flawed business model, which profited from excessively high healthcare costs; (3) UnitedHealthcare had purportedly launched a competitor, Naviguard, to reduce its business with MultiPlan and bring the over-priced and conflicted services offered by MultiPlan inhouse; and (4) MultiPlan had suffered from material, undisclosed pricing pressures that had caused it to slash the “take rate” it charged customers in half in some instances and falsely characterized revenue declines as “idiosyncratic” when in fact they were due to sustained, negative pricing trends afflicting MultiPlan’s business.

Following this news, the price of Churchill III’s securities declined. By November 12, 2020, the price of Churchill III’s Class A common stock fell to a low of just $6.12 per share, nearly 40% below the price at which shareholders could have redeemed their shares at the time of the shareholder vote on the Merger.

The complaint alleges that the Proxy failed to disclose among other things that: (a) MultiPlan was losing tens of millions of dollars in sales and revenues to Naviguard, which threatened up to 35% of Churchill III’s sales and 80% of its levered cash flows by 2022; (b) sales and revenue declines in the quarters leading up to the Merger were not due to “idiosyncratic” customer behaviors as represented, but rather due to a fundamental deterioration in demand for MultiPlan’s services and increased competition; (c) MultiPlan was facing significant pricing pressures for its services and had been forced to materially reduce its take rate in the lead up to the Merger by insurers; (d) as a result of the foregoing, MultiPlan was set to continue to suffer from revenues and earnings declines, increased competition and deteriorating pricing dynamics following the Merger; and (e) as a result of the foregoing, Churchill III investors had grossly overpaid for the acquisition of MultiPlan in the Merger, and MultiPlan’s business was worth far less than represented to investors.

MultiPlan investors may, no later than April 26, 2021, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. In order to be appointed as a lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.

Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country involving securities fraud, breaches of fiduciary duties and other violations of state and federal law. Kessler Topaz Meltzer & Check, LLP is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world. The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars). The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com.

CONTACT:
Kessler Topaz Meltzer & Check, LLP
James Maro, Jr., Esq.
Adrienne Bell, Esq.
280 King of Prussia Road
Radnor, PA 19087
(844) 887-9500 (toll free)
(610) 667-7706
[email protected]

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/investor-alert–kessler-topaz-meltzer–check-llp-reminds-investors-of-securities-fraud-class-action-lawsuit-filed-against-multiplan-corporation-mpln-301261286.html

SOURCE Kessler Topaz Meltzer & Check, LLP

Subversive Acquisition LP Announces InterCure’s Letter of Intent Relating to the Acquisition of a Multi-National Medical Cannabis Producer, Better Holdings

InterCure Signs Letter of Intent with Cann Pharmaceutical Ltd.

Acquisition Strengthens InterCure’s Position as the Largest Cannabis Company Outside of North America

TORONTO, April 05, 2021 (GLOBE NEWSWIRE) — SUBVERSIVE ACQUISITION LP (TSX: SVX.U, NEO: SVX.U, OTCQX: SBVRF) (“SVX”) announced today that InterCure Ltd. (dba Canndoc) (TASE: INCR) (“InterCure”), Israel’s leading cannabis company and SVX’s intended target for its “Qualifying Transaction” (the “Transaction”), has signed a Letter of Intent (“LOI”) with Cann Pharmaceutical Ltd. (“Cann”) to acquire Better Holdings (“Better”), a pioneering medical cannabis operator in Israel and Australia. Under the terms of the agreement, InterCure will acquire 100% of Cann’s shares, which includes Better’s operations in Israel and 50% of Cann Pharma’s shares, which owns the commercial rights to develop cannabis-based medical products.

Transaction Highlights

  • InterCure’s acquisition of Better creates the largest cannabis company outside North America
  • The Better acquisition expands InterCure’s global reach and accelerates international expansion strategy to major markets worldwide.
  • The companies expect to sign detailed and binding agreements within 90 days.

Cann is a pioneer of medical cannabis in Israel, with leading expertise in cannabis research, cultivation, marketing, and commercialization of medical cannabis products for thousands of patients to treat a variety of medical indications approved by the Ministry of Health. Its leading brand, “Better” is driven by a unique genetic portfolio that is consistently in high demand among medical cannabis patients in Israel and have gained international recognition. In 2019, Better received approval for a phase II clinical trial of its lead therapy, EP1, in Australia. The treatment is indicated for refractory epilepsy in children and adolescents who have not responded to pharmacological treatment. The total consideration will be USD $35 million, which will be payable with InterCure shares, at the same valuation used in connection with the Transaction. The noted shares will be subject to a three-year lock-up period, where each year up to one-third of the shares will be released from the lockup using a monthly release mechanism. InterCure will also invest up to USD $2.5 million in Better Australia in consideration for an 11% ownership stake with Cann’s shareholders committing to making a parallel investment on the same terms.

Ehud Barak, InterCure chairman, said: “Today’s announcement is a historical milestone in the Israeli cannabis industry as we prepare to add Better, a pioneer of our industry, to the InterCure family. We believe our combined business strengths and capabilities will help us to connect more effectively with new and existing patients in Israel and internationally. Once the transaction is completed, InterCure’s portfolio will include additional leading brands, distribution network, and unique partnerships, positioning us to deliver sustainable value for all stakeholders.”

Alexander Rabinovitch, InterCure CEO, said: “InterCure and Better Holdings’ combined business operations create a new international cannabis industry force that will further accelerate our global expansion plans and opportunities.”

About SVX

Subversive Acquisition LP is a limited partnership established under the Limited Partnerships Act (Ontario) formed for the purpose of effecting, directly or indirectly, an acquisition of one or more businesses or assets, by way of a merger, amalgamation, arrangement, equity exchange, asset acquisition, equity purchase, reorganization, or any other similar business combination involving SVX that will qualify as its qualifying transaction for the purposes of the rules of the TSX and Neo Exchange Inc. SVX is a special purpose acquisition corporation for the purposes of the rules of the TSX and Neo Exchange Inc.

For more information, visit https://www.subversivecapital.com/svx.

About Subversive Capital

Subversive Capital is a leading investment firm dedicated to investing in radical companies whose core missions subvert the status quo. With almost a decade of experience in the global cannabis industry, Subversive Capital has lead investments in some of the most successful transactions in the industry including the recent launch and closing transaction of Subversive Capital Acquisition Corp. to form The Parent Company (TPCO Holding Corp.) currently traded on the Neo Exchange and OTCQX.

For more information, visit www.subversivecapital.com

About InterCure and Canndoc

InterCure (TASE: INCR) is the first public company on the Tel Aviv Stock Exchange to hold a valid and permanent license for the medical cannabis value chain through its 100% ownership in Canndoc. Canndoc is a GMP medical cannabis producer. Licensed by the Israeli Ministry of Health since 2008, Canndoc is a leading pioneer in the research, cultivation, production, and distribution of pharma-grade cannabis-based products to patients, hospitals, pharmacies, research and governmental organizations.

Through its strategic exclusive collaboration with world leaders, distribution agreement with SLE (100% owned by Teva Pharmaceutical Industry) and long-term sales agreements, Canndoc is well-positioned as a leading and significant player in pharma-grade medical cannabis in Israel, Europe and the United Kingdom.

For more information: http://www.canndoc.com

About Better

Since 2008, Better has been developing, cultivating, and marketing dedicated cannabis strains for conditions and diseases such as epilepsy, autism, chronic pain, and cancer, treating approx. 10 thousand patients every month. In 2019, Better received approval for a phase II clinical trial of its lead therapy, EP1, in Australia. The treatment is indicated for refractory epilepsy in children and adolescents, who have not responded to pharmacological treatment.

In Israel, Better operates two cultivation spaces with a commercial growth potential of over 5 tons of medical cannabis a year (as of mid-2020) from unique, stable cannabis strains of its development. Better has acquired a reputation as a trailblazer in the cultivation of medical cannabis with advanced techniques that ensure safe, clean, and consistent quality cannabis products on the market. Better’s cultivation methods are completely chemical-free throughout the plant’s cultivation process.

Forward‐Looking Statements

This press release may contain forward-looking information within the meaning of applicable securities legislation which reflects SVX’s current expectations regarding future events. The words “will”, “expects”, “intends” and similar expressions are often intended to identify forward-looking information, although not all forward-looking information contains these identifying words. Specific forward-looking information contained in this press release includes, but is not limited to: statements concerning the consummation of the transactions pertaining to the LOI, the synergies created, InterCure’s expected benefits and subsequent investment in Better Australia and matters relating to, the Transaction and the satisfaction of the required closing conditions. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond SVX’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. Such risks and uncertainties include, but are not limited to: failure to complete the Transaction and the transactions contemplated by the LOI, changes in general economic, business and political conditions, changes in applicable laws, the U.S. and Canadian regulatory landscapes and enforcement related to cannabis, changes in public opinion and perception of the cannabis industry, reliance on the expertise and judgment of senior management, as well as the factors discussed under the heading “Risk Factors” in the non-offering prospectus pertaining to the Transaction which is available on SEDAR at www.sedar.com. SVX undertakes no obligation to update such forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

FOR FURTHER INFORMATION PLEASE CONTACT:

Subversive Acquisition LP

Investors:
[email protected]

Media:
Berrin Noorata
[email protected]

InterCure Ltd.

Adam Haliva, Global Investor Relations
[email protected], (972) 54-646-8778



Wynn Golf Club Launches Exclusive Golf Vacation Offer With Ship Sticks

PR Newswire

LAS VEGAS, April 5, 2021 /PRNewswire/ — Wynn Golf Club invites guests to experience the only resort golf course on the Las Vegas Strip this spring with an exclusive new golf getaway vacation package, available now through June 30, 2021. With a focus on wellness, the retreat features several luxury upgrades that eliminate stress and increase relaxation, including a special discount from Ship Sticks, the golf industry’s premier shipping provider that can deliver guests’ golf clubs and luggage directly to the resort.

Two-night packages start from $595 weekday and $675 weekend and include:

  • Deluxe accommodations at Wynn Las Vegas or Encore
  • Complimentary room upgrades on select room types
  • One round of golf at Wynn Golf Club
  • 20% savings on shipping with Ship Sticks offering door-to-door service that makes traveling with golf clubs and luggage convenient, safe, and reliable
  • Choice of $100 credit for dining or use at The Spa at Wynn
  • Full terms and conditions can be found here

To book the Wynn and Ship Sticks Golf Retreat visit
www.wynnlasvegas.com/offers
 

The Wynn Golf Club, an 18-hole championship course designed by legendary golf course architect Tom Fazio, offers players a challenging and entertaining experience from the first drive to the last putt. The course sits on 129 acres of the resort’s private backyard, with eight all-new holes and 10 reimagined holes following a redesign by Fazio in 2019. Lush landscapes unique to desert golf include several water features and streams, 100,000 shrubs, and 7,000 mature trees, many of which date back to the 1950s when the land was home to the historic Desert Inn Golf Club.

Par is 70 with a total yardage that stretches from 4,810 to 6,722 with a choice of four tees. A new 6,500-square-foot practice putting green sits adjacent to the first tee, along with a netted full swing warm-up area. The signature 18th hole culminates on a green framed by a 35-foot-tall by 100-foot-wide waterfall for a truly spectacular finish.


About Wynn Las Vegas

Wynn Resorts (Nasdaq: WYNN) is the recipient of more Forbes Travel Guide Five Star Awards than any other independent hotel company in the world, and in 2021 was once again honored on FORTUNE Magazine’s World’s Most Admired Companies list for the thirteenth time. Wynn and Encore Las Vegas consist of two luxury hotel towers with a total of 4,748 spacious hotel rooms, suites and villas. The resort features approximately 194,000 square feet of casino space, 20 signature dining experiences, 11 bars, two award-winning spas, approximately 560,000 square feet of meeting and convention space, approximately 160,000 square feet of retail space as well as two showrooms, two nightclubs, a beach club and recreation and leisure facilities, such as the recently renovated Wynn Golf Club and 18-hole, 129-acre championship golf course. For more information visit press.wynnlasvegas.com.


About Ship Sticks

Founded in 2011, Ship Sticks is the world’s premier, white-glove golf club shipping service. Trusted by more than 3,500 world-class golf facilities, Ship Sticks has assisted customers in shipping their gear over 1 billion miles worldwide, utilizing dependable shipping networks such as FedEx, UPS, and DHL.  Ship Sticks has won Golf Digest Editors’ Choice Award for “Best Golf Club Shipper” six years in a row. The service provides an affordable, on-time, door-to-door shipping service designed to eliminate the need to carry, check, and claim baggage at the airport. The hassle-free service will pick up your golf clubs and luggage directly from your home, office, country club, or resort and deliver them to your destination.  As a company created by golfers, for golfers, Ship Sticks makes traveling with golf clubs and luggage safe and reliable with unmatched convenience. For more information visit www.shipsticks.com

Contacts:

Eric Kreller, Wynn Las Vegas
702.770.3740
[email protected] 

Justin Metzl, Director of Marketing
561-232-2185
[email protected]

 

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/wynn-golf-club-launches-exclusive-golf-vacation-offer-with-ship-sticks-301261778.html

SOURCE Wynn Las Vegas

Zep Takes a Stand for Sustainability with New Stewardship Focus

Zep Takes a Stand for Sustainability with New Stewardship Focus

Zep, Inc. Launches New Company-Wide Initiative to Build a Safer and Cleaner Future

ATLANTA–(BUSINESS WIRE)–
There is growing demand from employees, customers, and investors for companies to do more than deliver financial returns. Today’s conscious consumer expects companies to contribute positively to environmental and social causes. Zep, Inc., an innovator, producer and distributor of maintenance, cleaning, and sanitation solutions, announced today the launch of Zep Stewardship, a new company-wide initiative to make the planet safer, cleaner, and more productive.

Zep Stewardship is an Environmental Social Governance (ESG) strategy that aligns with Zep’s key values: Stewardship, Passion for Problem Solving, Empowerment, Expertise, and Doing the Right Thing. In 2020, Zep conducted an extensive ESG materiality assessment based on Global Reporting Initiative (GRI) Sustainability Reporting Standards to develop and inform its priority areas.

“Zep Stewardship is only the beginning of our commitment to keep people safe and to a build a cleaner and more productive world. This promise starts with our employees, customers, and communities,” said Matt Duncan, Zep’s Chief Administrative Officer. “We built Zep Stewardship from the inside out, enlisting the insights, leadership and support of our people and customers and referencing reputable ESG guidelines and standards to inform our goals and vision.”

Zep Stewardship focuses on five key areas: health and safety, carbon emissions, water usage and effluents, diversity and inclusion, and marketing and labeling.

Health and Safety

  • We are dedicated to being our customers’ leading partner for pandemic preparedness and biosecurity innovation. For example, Zep Assure™ is a new comprehensive cleaning and disinfection management compliance system that assists customer efforts to fight the spread of COVID-19 and other micro-organisms, and to protect employees and guests.
  • Zep continues to pursue Target Zero workplace incidents, and in 2020 deployed new technology to enhance real-time reporting with intent to reduce future employee injuries. We firmly believe employees have a right to safe work environments, and all employees have a role to play in enhancing our processes and practices.

Carbon Emissions

  • We are committed to reducing carbon emissions from our operations and, through our solutions, from those of our customers. In 2020, we reduced our footprint through optimized shipment of goods, reduced travel and reduced facility requirements. In 2021, Zep will further refine baseline data to inform our long-term carbon emissions reduction strategy and targets.

Water Usage and Effluents

  • We are committed to reduce water use and effluents in our own value chain, and in that of our customers. In 2020, we updated baseline water and environmental management performance and identified best practices with the goal to scale them across the organization.
  • Zep commissioned a major water reuse technology serving our Chambersburg, Pa., plant and enhanced waste reduction equipment in our Emerson, GA facility. In partnership with customers, Zep continues to expand uniquely sustainable industry solutions such as SureFill, DynaClean, and AFCO Smart Track.

Diversity and Inclusion

  • We believe commitment to Diversity and Inclusion enables Zep to contribute more fulsomely to society and to a more successful enterprise. We created employee action committees and diversity and inclusion roundtables to continue our commitment to an inclusive workplace that reflects the uniqueness of its employees, customers, and suppliers.
  • In 2020, we filled four senior leadership positions with diverse candidates and formed a strategic partnership with a significant minority owned business. By 2025, we plan to substantially increase share of business with minority-owned suppliers and enhance overall gender and ethnic diversity by 20%.

Marketing and Labeling

  • We believe in delivering customers efficacious products that minimally impact our environment. We have implemented a company-wide formulation policy to improve environmental and safety performance of products and continue to support customers in ensuring compliance to evolving chemical regulations.

“Zep Stewardship is a step toward more transparency, better procedures for environmental and occupational safety and more support for our communities,” Duncan said.

To learn more about Zep Stewardship and the company’s purpose to make the planet safer, cleaner, and more productive, visit www.zepstewardship.com.

About Zep, Inc.

Zep, Inc. is a leading innovator, producer, and distributor of maintenance, cleaning, and sanitizing solutions for food & beverage, industrial & institutional, retail, and vehicle care customers. Zep possesses a large portfolio of premium brands built over an 80+ year legacy of developing the most effective products trusted by professionals and consumers to get the job done right the first time.

Amber Rice

[email protected]

(470) 795-8108

KEYWORDS: United States North America Georgia

INDUSTRY KEYWORDS: Environment Human Resources Infectious Diseases Chemicals/Plastics Professional Services Manufacturing Philanthropy Health Other Philanthropy

MEDIA:

Logo
Logo